Life Sciences Archive » February, 2025

Life Sciences - February, 2025

275 articles

• Align Tech Deal Directs Buyers To A Monopolist, Judge Says
• J&J Talc Spinoff Wraps Two-Week Chapter 11 Trial
• Fenwick Adds Longtime Startup Attorney To Insurtech Group
• Sterilization Plant Head 'Shocked' By EPA Cancer Risk Report
• Trump Can't 'Erase' Trans People Via Order, Wash. Judge Says
• Group Blasts Judge's Call For Women In Contraception MDL
• Robotic Surgery Co. Appealing Tossed Intuitive Antitrust Case
• Dartmouth Wants Fed. Circ. To Ax Fees After Vitamin IP Loss
• Drug Kickback Ruling Will Make FCA Liability Harder To Prove
• Aimmune Shareholders' $27.5M Deal Over Sale To Nestle OK'd
• Bioventus Hit With Del. Derivative Suit After NC Class Deal
• NFL Alums Say Vaccine Fund Misuse Claims Should Fail
• Assessing PE Risk After Mass. False Claims Act Amendments
• China Signals Retaliation Following Extra 10% US Tariff
• Taxation With Representation: Gibson Dunn, Skadden
• Goodwin, White & Case Build BridgeBio's $949M SPAC Deal
• Don't Fault Sterilization Co. For What It Didn't Know, Jury Told
• Liquidia Challenge To UTC's Tyvaso Exclusivity Fails
• CooperSurgical Says Unique IVF Claims Require Separate Trials
• What Trump Actions Mean For Federal Research Funding
• $40M Deal OK'd For Suit Over Emergent Vax Flub
• CVS Freed From Hospital's Suit Over Drug Pricing Program
• OpenEvidence Says Rival's Attack Targeted Its AI 'Blueprint'
• Lead Testing Co. Director To Admit False Statements
• DOJ Says It Will No Longer Defend DEA Admin Judges
• Ex-Worker Says Manufacturer Fails To Pay For Off-Clock Work
• 4th Circ. Rips 'Shaky At Best' Drug Price-Fixing Class Action
• McCarter & English Wants $3.8M, Ex-Client Wants New Trial
• Lenders Can't Claim Ex-Mylan VP's $4M Insider Trade Penalty
• Medical Device Co. Inks €760M Deal, Unveils Separation Plans
• How Courts Can Filter Nonmeritorious Claims In Mass Torts
• Anthropic Could Hit $62B Valuation, And More Deal Rumors
• Racing Corvettes Makes Me A Better Lawyer
• Merck, Glenmark Trim United Healthcare's Zetia Antitrust Suit
• Trump Orders Fed Agencies To Plan For Large Layoffs
• Simpson Thacher Adds Partner From Wilson Sonsini
• Planned Parenthood Immune From FCA Suit, 5th Circ. Says
• GOP-Led House Panel Pushes Easier Rules On Capital Raising
• CBD Co. Sues Rivals Over Topical Treatment Patents
• Attorneys Must Act Now To Protect Judicial Independence
• CVS Ordered To Comply With FTC's PBM Subpoena
• Walgreens Inks $595M Deal To End COVID-19 Testing Suit
• Pa. Biotech Co. Can't Escape $4M Trade Secrets Award
• Trump Says Transgender Order Shields Kids From Danger
• Sterilization Co. Can't Pin Cancer On Genetics, Jury Told
• Chancery Likens Claims To Recycling Losing Lottery Ticket
• Trump Demands Enforcement Of Healthcare Price Disclosures
• Kroger Seeks More Sanctions For Prolific Consumer Atty
• J&J Says Samsung Is Breaking Deal Over Stelara Biosimilar
• Insulet May Face Choice: $452M Award Or Stifling Rival
• Rethinking 'No Comment' For Clients Facing Public Crises
• Couple, Biotech Co. Jointly Drop Lost Embryos Suit
• Purdue Gets Time To Document New $7.4B Ch. 11 Settlement
• Masimo Aims To DQ Hueston Hennigan As Ex-CEO's Counsel
• Lawyer Who Became Client's 'Punching Bag' Scores Case Exit
• WilmerHale, Cleary Steer $4.1B Thermo Fisher-Solventum Deal
• Dental Co. Biolase Drills Down On Unopposed Ch. 11 Plan
• Natera's $96M DNA Test Verdict Scrapped, Patents Axed
• Fed. Circ. Shouldn't Assume Doctors Read Labels, Profs Say
• Bioanalysis Co. Worker Fired For Flagging FDA Data, Suit Says
• Biotech Minority Investor Sues In Del. To Block Control Moves
• Insurer Needn't Cover Hospital's $2.5M Virus Vax Probe Costs
• PBMs To Challenge FTC Case At 8th Circ., But Without Pause
• Purdue's New Ch. 11 Plan Sidesteps Nonconsensual Releases
• As Failure-To-Warn Preemption Wanes, Justices May Weigh In
• Boehringer Ingelheim Wins Illinois Zantac Cancer Retrial
• Skadden, Ropes & Gray Advising On 23andMe Buyout Bid
• How Design Thinking Can Help Lawyers Find Purpose In Work
• Elizabeth Holmes Loses 9th Circ. Appeal Over Theranos Fraud
• Justices Nix Whistleblower Suit Over Arbitral Vacatur Limits
• Paul Hastings Adds Boston Co-Chair For New Tech Practice
• Colo. Woman Tells Jury Sterilization Plant Caused Cancer
• WebMD Users Secure Class Certification In Video Privacy Suit
• MSN Calls Novartis' Entresto Delisting Protest 'Disingenuous'
• Eli Lilly Has Exclusivity Over Weight Loss Drug, FDA Says
• Harry Manbeck, Former USPTO Head, Dies At 98
• NFL Alums Accused Of Misusing COVID Outreach Funding
• Pharma Co. Investors Get Final OK For $3M Settlement
• The Fate Of Biden-Era Clinical Study Guidance Under Trump
• Trending At The PTAB: Insights From 2024 Fed. Circ. Statistics
• Manufacturer Not Covered For Pot Grower Claims, Court Told
• UChicago Medical Center Can't Duck Wage Suit
• Weight Loss Drug Patient Drops Appeal In Cancer Risk Suit
• Weight Drug Suits Highlight Need For Legal Work On Safety
• 10 Issues To Watch In Aerospace And Defense Contracting
• Veolia Ends One Of Few Remaining Flint Water Suits For $53M
• Paul Hastings Seeks To End GenapSys Malpractice Action
• NJ High Court Takes Up Pharma Co. Fraud Coverage Row
• WilmerHale Corporate Ace Joins DLA Piper In California
• Del. Justices' D&O Ruling Clarifies 'Related' Claim Analysis
• NIH Research Cuts Stay On Hold As Judge Mulls Objections
• Compliance Pointers For DOJ's Sweeping Data Security Rule
• DOJ Says Job Protections For ALJs Are Unconstitutional
• Trump Trans Edicts Will Cause More Teen Suicides, States Say
• Generic-Drug Group Rallies Behind Appeal In Entresto Fight
• Boston, Other Cities And MassBio Back Challenge To NIH Cuts
• Green Groups Ask 9th Circ. To Press EPA Again On Atrazine
• Feds Say DC Judge Can't Bar 'Hypothetical' Spending Freezes
• Drug Buyers Get OK On $275M Sandoz Antitrust Settlement
• Ex-Heritage Pharma CEO Disciplined Over Price-Fixing Case
• Ex-Opioid CEO's Billing Spat With Trial Atty Lands In Court
• Research Co. Liable For Bungling $52M COVID-19 Mask Deal
• Competitive Weightlifting Makes Me A Better Lawyer
• What To Know About Trump's Likely Pick For USPTO Director
• Walgreens Says $1B COVID Testing Award Must Be Nixed
• Colorado Joins Fight Against Trump Trans Health Order
• Ga. Woman Implanted With Wrong Embryo Sues Fertility Clinic
• Gilead, Janssen Settle HIV Treatment Suits With Lupin, Apotex
• COVID Fraudsters Get Prison For Trying To 'Make A Buck'
• Judge Won't Halt PBM Case Over Attack On FTC Independence
• Fla. Court Won't Revive Property Manager's COVID Claims
• 3rd Circ. Doubts Alleged Cancer Risk Devalued Drug
• LA Gardasil Trial Against Merck Bagged After 3 Weeks
• BP Must Face Contract Claim In Bayer's $12M Benzene Suit
• The Case For Compliance During The Trump Administration
• Wu-Tang Album Owner Wants Shkreli To Pay Fees
• Simpson Thacher Adds Litigator, Private Funds Pro In Boston
• 1st Circ. Backs Strict View Of Kickback Law In Blow To FCA
• Hikma Appeals To Justices In 'Skinny Label' Patent Case
• Studies Don't Show Zantac Cancer Risks, Jury Hears
• J&J Talc Unit Launches 2-Week $10B Ch. 11 Settlement Trial
• Novo Nordisk Queues Up $830M Suit Over Disappointing Drug
• Convicted Pharma Exec Seeks Trial Redo, Citing Feds' Error
• Human Rights Atty Sees 'Serious Risks' Of Neural Data Abuse
• Trump Issues Order Calling For Expanded IVF Access
• Trump Trans Order Is Unconstitutional 'End-Run,' Judge Says
• Vaccine Developer Files Ch. 11 Sale Plan With $11.5M Bid
• A Look At HHS' New Opinion On Patient Assistance Programs
• Ex-Goldman Atty Squires Expected To Be Named USPTO Head
• FTC's Ferguson, PBMs Agree: Nix Leader Removal Safeguards
• Digital Health Co. Beats Some Claims In SPAC Investor Suit
• Fed. Circ. Risks Relying On 'Science Fiction,' Justices Told
• Trump Admin To Cut Thousands Of Federal Health Employees
• New Delisting Rules Shorten Leash For Distressed Companies
• CVS Wins Arbitration In Medicare Fee Antitrust Suit
• Fed. Circ. Rejects COVID Test Suit In Gilstrap-Authored Ruling
• Some Discovery On Hold In Abbott Infant Formula Case
• Fed. Circ. Ruling Shows Even Small Cos. Can Win At ITC
• 8 Things Attys Should Know About Conn.'s $55B Budget
• Judge Upholds Pay-For-Delay Ban Law, But Only In Calif.
• Camston Wrather Files For Ch. 7 With Over $100M In Debt
• Tariffs On Drugs And Chips May Not Bring Makers Stateside
• Inconsistent Injury-In-Fact Rules Hinder Federal Practice
• 2nd Judge Blocks Trump Trans Health Order, Chides DOJ Atty
• Mallinckrodt Fails To Halt Airgas' Generic Nitric Oxide Drug
• DC Judge Affirms Approval Of Teva's Generic Sleep Drug
• Long-Term Zantac Use Raised Cancer Risks, Jury Hears
• Maryland Judge Blocks Trump's Orders On Trans Healthcare
• 2 Anti-Kickback Developments Hold Lessons For Biopharma
• Merck Investor Sues Over Gardasil China Market Projections
• In-House Counsel Pointers For Preserving Atty-Client Privilege
• 9th Circ. Upholds DEA Denial Of Psilocybin Petition
• How SDNY US Atty Nom May Shape Enforcement Priorities
• Musk's $97B OpenAI Bid Dubbed A 'Stunt' Amid Other Rumors
• Robert F. Kennedy Jr. Confirmed, Sworn In As HHS Secretary
• Paul Hastings, Cooley Lead Obesity-Focused Aardvark's IPO
• Greenberg Traurig Adds Goodwin Life Sciences Pro In Texas
• Judge Finds No Infringement In Alcon's Eye Drop Patent Suit
• Bausch Health Beats Suit Over 'Faking' Financial Stability
• Supply Co. Files Failsafe $387M Suit Amid Threat Of Dismissal
• Aurion Tells Del. Justices IPO Delayed Amid Investor Battle
• Labcorp Can't Score New Trial After $384M Patent Loss
• Paraquat Plaintiffs Urge 7th Circ. To Revive MDL Suits
• RI Judge Won't Pause Order To Unfreeze Funds Amid Appeal
• Ga. Judge Trims Untimely Paragard IUD Claims From MDL
• Boston's Opioid Damages Claims Tossed As Too Late
• Improving Comms Between Trial Attys And Tech Witnesses
• What's Next For State Regulation Of Hemp Cannabinoids
• Collecting Rare Books Makes Me A Better Lawyer
• Wash. Health Privacy Law Debuts In Amazon Tracking Suit
• Medtronic, Axonics Agree To End Bladder Control Patent Fight
• Kratom Producers Hid 'Addictive' Risks, Consumers Say
• Teva Says Mixed Coreg Rulings Undermine GSK Damages Bid
• J&J Allies Dub Milestone Fee Reversal 'Crucial' To Del.
• Novo Nordisk Mostly Escapes Insulin Pen Contamination Suit
• MSN Urges Fed. Circ. To Reinvalidate Novartis' Entresto IP
• Split 3rd Circ. Keeps Merck Vaccine Antitrust Panel Immunity
• Research Org Faces Investor Suit Over Customer Cost-Cutting
• New DOJ Leaders Should Curb Ill-Conceived Prosecutions
• A 'Disaster For Science': Universities Sue Over NIH Grant Cap
• Tips For Pharma-Biotech Overlap Reporting In New HSR Form
• CVS, Aetna Escape Testing Lab's $20.6M Unpaid Invoices Suit
• DC Judge Orders Restoration Of Public Health Webpages
• Judge Should Not Have Been Reprimanded For Alito Essay
• Novartis To Buy US Pharma Biz Anthos For Up To $3.1B
• Pharma Co. Misled Investors On Depression Drug, Suit Says
• Fed. Circ. Preserves Corning's Win In Gene Therapy Fight
• GenapSys Can't Claw Back Some Docs From Paul Hastings
• DC Judge Questions Abrupt Removal Of Public Health Info
• Fed. Circ. Revives Cotter's Radiation Injury Suit Indemnity Bid
• A Look At Drug Price Negotiation Program's Ongoing Impact
• Congress Must Consider Accurate Data About Patent Thickets
• PBMs Fight To Keep Mich. AG's Opioid Suit In Federal Court
• Jazz Pharma Drops Last Defendant From Epidiolex Patent Suit
• Fighting Cancer Has Impaired Life, Zantac Plaintiff Testifies
• Mass. Judge Temporarily Blocks NIH Funding Cuts
• Life Sciences Group Of The Year: Fenwick
• Trump Admin Violating Order To Unfreeze Funds, Judge Says
• Lights, Camera, Ethics? TV Lawyers Tend To Set Bad Example
• Biotech Firm Omega Therapeutics Hits Ch. 11 To Restructure
• Trump Isn't Obeying Order To Unfreeze Funds, States Say
• NC Judge Knocked By Fed. Circ. For Rushing Patent Trial
• NJ Statehouse Catch-Up: Offshore Wind, AI, Neurodiversity
• 70 Depo-Provera Suits Joined In Florida's Northern District
• SPAC Market Hums Again Following Multiyear Downturn
• Fed. Circ. Backs Ventria Cell Culture Patent Win At ITC
• Fed. Circ. Considers Some Testing For Avadel Sleep Drug
• Pa. Medical Pot Co. Beats Consultant's IP Breach Claims
• Del.'s Quiet Ambition To Tweak Chancery, Stem Feared DExit
• Trump Drops High Court Opposition To Transgender Care Ban
• Life Sciences Group Of The Year: Cooley
• Taxation With Representation: Kirkland, Latham, Skadden
• Will 4th Time Be A Charm For NY's 21st Century Antitrust Act?
• Accountant-Owned Law Firms Could Blur Ethical Lines
• 3 Firms Guide Bain On $3.4B Japanese Pharma Co. Buy
• UK Litigation Roundup: Here's What You Missed In London
• Doctors Org. Wants Health Agency Website Info Restored
• Tom's 'Natural' Kids Toothpaste Has Lead, Arsenic, Dad Says
• Sterilization Plant's 'Royal' Mistake Leaked Pollution, Jury Told
• Goodwin, Ropes Lead Cystic Fibrosis Co.'s Upsized $191M IPO
• Buyers Want Kratom Cos. Addiction Suit To Go On
• CooperSurgical Hit With IVF Embryo Loss Class Claims
• Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row
• UnitedHealth Drops Bid To Toss Home Health Deal Challenge
• EIP Grows US Team With 2 Pranger Law Attys
• GSK's Zantac Woes Gave Investors Heartburn, Suit Says
• Globus Medical Buys Device-Maker Nevro In $250M Deal
• The Post-Macquarie Securities Fraud-By-Omission Landscape
• Life Sciences Group Of The Year: Freshfields
• Harvard Biotech Patent Case Ends With Mid-Trial Deal
• AI Will Soon Transform The E-Discovery Industrial Complex
• Sterilization Co. Skimped On Pollution Controls, Residents Say
• Colo. University Hit With Suit Over 'Culture Of Chauvinism'
• Wachtell, Skadden Guide Becton's Bid To Sell Diagnostics Biz
• Dickinson Wright Continues IP Growth With Chicago Hire
• IP, Licensing, M&A Trends To Watch In Life Sciences This Year
• Injectable Drug Device Maker West Pharma Secures Ban At ITC
• CVS Beats 2nd Investor Suit Over Omnicare Deal
• 6th Circ. Urged To Revive Allergy Co.'s Antitrust Claims
• When Innovation Overwhelms The Rule Of Law
• Life Sciences Group Of The Year: Hogan Lovells
• Activist Nominates 4 Director Candidates To Kenvue Board
• McKesson, Others Beat Indirect Drug Reseller Price-Fix Suit
• Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order
• Fed. Circ. Grapples With Extensions On Reissued Patents
• Carcinogenic Risk Unknown When BI Owned Zantac, Jury Hears
• McKesson Paying $850M For Top Stake In Eye Health Co.
• Anticipating Direction Of Cosmetics Regulation Under Trump
• Drug Pricing Policy Trends To Expect In 2025 And Beyond
• 'Sloppy' Work Hurts Lab's $20.6M Insurance Suit, Judge Says
• Docs Say DEA Didn't Put All Documents In Pot Hearing Record
• Doctors Org. Sues Over Health Agency Website Purges
• Life Sciences Group Of The Year: Latham
• Imagine The Possibilities Of Openly Autistic Lawyering
• Mintz Adds Dentons West Coast Corporate Head In San Diego
• Javice's Texts About Elizabeth Holmes Not Fair Game For Trial
• Party-Line Vote Sends Kennedy's HHS Nomination To Senate
• 6th Circ. Axes $650M Judgment Against CVS, Walgreens
• Apple Seeks Bench Trial Win In Masimo's Trade Secret Suit
• DOJ Poised To Prosecute Threat-Makers Against DOGE
• Zantac's Discoloration Merely 'Cosmetic,' Boehringer Rep Says
• Allergan Tells 4th Circ. Medicaid Pricing Suit Rightly Tossed
• Baby Sock Co. Inks $3.5M Deal In Investor's FDA Approval Suit
• Pro-Palestine Protesters Say UMich Bans Trample Rights
• PharmacyChecker's Legality Weighed In 9th Circ. Appeal
• Top 10 Healthcare And Life Sciences Issues To Watch In 2025
• Parsing 3rd Circ. Ruling On Cannabis, Employee Private Suits
• 4 Keys To Litigating In An Active Regulatory Environment
• J&J Investigations And Gov't Litigation Head Joins O'Melveny
• Asbury Park, Zoning Board, Again Escape Pot Co.'s Suit
• Cystic Fibrosis Drug Developer Sionna Targets $150M IPO
• DC Judge Joins RI In Blocking Trump Funding Freeze
• Kiromic SEC Order Shows Importance Of Self-Reporting
• Documentary Filmmaking Makes Me A Better Lawyer
• Goodwin Hires Kirkland Antitrust Partner In DC